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Abstract 
 
Diamond-Blackfan anemia (DBA) is a rare congenital erythroblastopenia and inherited bone 
marrow failure syndrome that affects approximately seven individuals in every million live births. 
In addition to anemia, about 50% of all DBA patients suffer from various physical malformations 
of the face, hands, heart, or urogenital region. The disorder is almost exclusively driven by 
haploinsufficient mutations in one of several ribosomal protein (RP) genes, although for ~30% of 
diagnosed patients no mutation is found in any of the known DBA-linked genes. Because DBA 
is such a rare disease with a particularly wide range of clinical phenotypes and molecular 
signatures, the development of collaborative efforts such as the ERARE-funded European DBA 
consortium (EuroDBA) has become imperative for DBA research. EuroDBA was founded in 
2012 and brings together dedicated clinical and biological researchers of DBA from France, 
Italy, the Netherlands, Germany, Israel, Poland, and Turkey to achieve a number of goals 
including the consolidation of data in patient registries, establishment of minimal diagnostic 
criteria, and projects aimed at more fully describing the different mutations linked to DBA. This 
review will cover the history of the EuroDBA registries, the methods used by EuroDBA in the 
diagnosis of DBA, and how the consortium has successfully worked together towards the 
discovery of new DBA-linked genes and the better understanding their pathophysiological 
effects.   
 
Keywords: Diamond-Blackfan anemia; ribosomal protein genes; ribosome biogenesis; pre-
rRNA processing; polysome profiling  
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Introduction 
 
Diamond Blackfan Anemia (DBA, OMIM #105650) is a rare congenital erythroblastopenia that is 
clinically and genetically very heterogeneous.1 It represents part of a group of rare genetic 
disorders known as the inherited bone marrow failure syndromes (IBMFS),2 and is characterized 
as a pure red cell aplasia that is also linked to physical malformations.3 Because nearly all the 
genetic lesions driving DBA to date have been found in ribosomal protein (RP) genes, DBA is 
considered a “ribosomopathy”.4 This term is applied to disorders in which the pathogenic 
mutation results in defective ribosome biogenesis and/or the ability of ribosomes to properly 
translate mRNAs into protein. 
 
The first description of DBA appears in a 1936 issue of Medicine in a chapter titled, “Anaemia of 
Infancy and Early Childhood” written by Hugh W. Joseph.5 However, the recognition of DBA as 
a specific clinical entity is attributed to the American pediatricians Louis Diamond and Kenneth 
Blackfan, who published a paper describing it in 1938.6 In its classical form, DBA affects 
approximately seven per one million live births and is characterized by a clinical presentation 
within the first year of life, macrocytic anemia with reticulocytopenia and a normocellular bone 
marrow with a paucity of erythroid precursors.7 However, in recent years and by increasing the 
disease awareness more patients with atypical DBA manifesting later in life (or previously 
misdiagnosed) are referred to specialized DBA clinics. Physical malformations occur in roughly 
50% of patients and include (among others) craniofacial and thumb deformities, short stature, 
cardiac and urogenital malformations.8 Neurological or cognitive problems are very rare in DBA. 
DBA patients generally exhibit increased levels of fetal hemoglobin and the activity of 
erythrocyte adenosine deaminase (eADA) is elevated in 80-85% of all patients.9; 10  The risk of 
DBA patients developing cancer is higher than normal, although the risk does not appear to be 
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as high as with other inherited bone marrow failures such as Fanconi anemia, Shwachman-
Diamond syndrome, or dyskeratosis congenita.11; 12   
 
Genetics of DBA 
 
The DBA genotype, similar to the phenotype, is highly heterogeneous. The vast majority of 
allelic variations in DBA genes are mostly sporadic or de novo (55% of cases) and familial in the 
remaining 45%. In several instances of patients inheriting the mutation from a parent, the parent 
will not show any overt phenotype and are considered “silent carriers”. Silent carriers may also 
exhibit only a macrocytosis without anemia and/or an elevated eADA. The first DBA-linked gene 
to be identified was RPS19 in 1999.13 Subsequent to this initial finding, the identification of other 
mutations were revealed in RPS24, RPS17, RPL5, RPL11, RPS10, and RPS26.14-17 Many other 
mutations in RP genes have been identified within the last ten years and today the list includes 
RPS7, RPS10, RPS15A, RPS17, RPS19, RPS24, RPS26, RPS27, RPS28, RPS29; RPL5, 
RPL9 (in review), RPL11, RPL15, RPL18, RPL26, RPL27, RPL31, RPL35, and RPL35A.18-25 
This list represents 20 of the 80 functional RP genes in humans.  
 
Based on published observations (and unpublished observations of EuroDBA partners) it can be 
noted that the majority (>90%) of mutations fall in only 6 genes (RPS19, RPL5, RPS26, RPL11, 
RPL35A, and RPS24), while all other genes (such as RPS29, RPS17, RPS7, RPS10, RPL15, 
RPL9 and others) are mutated only in very few DBA patients worldwide and account for less 
than 10% of all mutated cases. There is little doubt that more RP or ribosome-associated genes 
will be identified in DBA patients in the near future. 
 
All the RP gene mutations identified in DBA patients to date are heterozygous. Homozygosity is 
largely suspected to be lethal, a suspicion supported by the lethality of homozygous RP gene 
 5 
mutations in several animal models including zebrafish and mice 26; 27. A wide range of mutation 
types is evident and at least in some cases appears to depend on the particular RP gene. Most 
of the missense mutations have been identified in the RPS19 gene while predominantly 
nonsense mutations, small deletions or insertions, and splice site mutations are found in RPL5 
and RPL11.16; 28 Partial- and whole-gene deletions have been detected (depending on the study 
cohort) in 10-20% of DBA patients using various copy-number methods (quantitative PCR, 
multiplex sequencing [MLPA], CGH and SNP arrays), mostly in RPS17, RPL35A, and RPS19 
genes.29-31 
 
While DBA is considered almost exclusively linked to RP gene mutations, two non-RP genes 
have been reported in patients including GATA1 and TSR2.32-34 35 The TSR2 gene is related to 
ribosome biogenesis since it is involved in pre-rRNA processing and binds to eS26 (RPS26) 
protein. GATA1 gene encodes for the major erythroid transcription factor GATA1 and is not 
reported to be involved in ribosome biogenesis. 
 
In a substantial number of patients (approximately 30%) the underlying genetic defects remain 
unknown despite the routine screening of the known RP genes linked to DBA. However, with 
the increasing availability and diagnostic role of next generation sequencing methods, including 
multiplex gene sequencing and whole exome sequencing (WES), novel genetic defects are 
being slowly but steadily identified.36  
 
History of European DBA Registries 
 
The rarity of diseases like DBA makes it difficult for one institute or clinician to become the 
centralized point of patient care. This difficulty exacerbates collecting the already sparse amount 
of clinical and biological data and using them to generate meaningful genotype:phenotype 
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correlations. Thus the key to success when it comes to understanding and ultimately defeating 
DBA, or any other rare disease, is collaboration. Although national and international 
collaborations can be challenging, extraordinary progress has been made in developing, 
funding, and maintaining groups of clinical and biological researchers who share the same goal: 
To better understand and ultimately cure a specific rare disease such as DBA. 
 
DBA networks preceded the creation of formal patient registries in Europe. The pioneering 
group in 1995 included clinicians from France, Germany, Italy, England, Sweden, and 
Switzerland under the umbrella of the European Society for Pediatric Haematology and 
Immunology (ESPHI) and the Société d’Hématologie et d’Immunologie Pédiatrique (SHIP). 
Their goals were simple and straightforward: To share DBA clinical data and samples, to build 
registries, and to test new drugs.37-41 By working together this group shared a major 
achievement in 1999 with the discovery RPS19 as the first known DBA-linked gene.13 This 
gene, RPS19, still today remains the most commonly mutated gene found in ~25% of DBA 
patients and as such is routinely the first gene candidate sequenced when genotyping a patient. 
 
The first observational DBA patient registries were initiated in the Czech Republic in 1988 and 
officially announced in 1992.42 This was shortly followed by registries in the USA (DBAR, 
1993),42; 43 Germany (1993), France (1995) and Italy (1995). The Italian registry is maintained as 
an online registry freely accessible to clinicians.44 In a similar strive to create greater 
transparency and openness the Italian group developed the publically available online RP gene 
database including mutational data from countries worldwide in 2008 
(http://www.dbagenes.unito.it). This registry regularly updates DBA mutation data and remains 
the standard go-to database when researchers are querying the novelty of recently identified 
mutations in their patients.45  
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While the registries mentioned above contain the majority of European DBA patients due to the 
size of the host country’s population, it is not necessary for a country to be highly populated in 
order to establish a meaningful registry. This is illustrated by the Israeli registry, which was 
founded in 2007.46 Although Israel has a relatively low population, the respective registry 
contains virtually all known DBA patients in the country. This allows the registry data to be used 
for very precise statistical measurements of disease and phenotype frequencies that are far 
more difficult in larger countries. Another example is the incipient Dutch DBA registry, which 
was founded this year (in review). The fact that there are a limited number of clinics in close 
proximity that treat DBA patients in the Netherlands resulted in the establishment of a 
substantially sized registry in a very brief period of time.  
 
In contrast, the initiation of patient registries in large or heavily populated countries can seem 
like a daunting task. This is especially true in countries that may not have access to or funding 
for state-of-the-art molecular diagnostics. An example of this is Poland, before it became a 
EuroDBA member in 2016. From 1998-2016 genotyping of Polish patients had been performed 
in collaboration with Boston Children’s Hospital, which contributed to the discovery of RPL5, 
RPL11, RPS10, and RPS26 as DBA-linked genes.16; 17 Another example is Turkey. An 
estimated 100 patients were diagnosed with DBA in the various hematology clinics around the 
country. However, there was no centralized point of care until 2014 with the development of the 
Inherited Bone Marrow Failure Center at Hacettepe University in Ankara. Today, both Turkey 
and Poland are members of EuroDBA and have the necessary funding required to build their 
own patient registries and systematically genotype their own patients. 
 
The establishment of these patient registries represents a crucial step in creating a global DBA 
network. Beyond Europe, many other countries around the world have in recent years 
successfully established their own DBA patient registries (Table 1). The populations of countries 
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initiating these registries range from over a billion (China) to fewer than 3 million (Lithuania). 
Thus the size and population density of any given country should not be considered a deterrent 
when deciding to establish a patient registry for a rare disease.   
 
History of the European DBA Consortium 
 
In 2012, the European Union’s ERA-Net for Research Programs on Rare Diseases (ERARE) 
issued a transnational call specifically for Young Researchers. This call led to the founding and 
successful funding of the European Diamond-Blackfan Anemia consortium, EuroDBA. The 
original EuroDBA members were clinician scientists who were organizers of the two largest DBA 
patient registries in Europe at the time (Germany and in France) together with a biological 
researcher from the Netherlands. This consortium was initiated with three major goals. One was 
to identify and characterize novel genetic lesions in the registered patients who did not have a 
mutation in any of the known DBA-linked genes. The second was to fully clarify and disseminate 
up-to-date clinical treatments and guidelines for patient care. The third was to develop 
molecular and cellular methods, including the use of zebrafish models and patient cell lines, to 
more fully understand the pathophysiology of DBA.  
 
The EuroDBA network over the next years expanded to include as associated partners other 
European countries that hosted DBA patient registries, such as Poland, Czech Republic, Italy, 
Spain, and Israel. In 2015 the funding for EuroDBA was renewed and the consortium was able 
to formally include many of the aforementioned countries. Moreover, the renewal allowed for the 
inclusion of the clinical groups in Poland, Turkey, as well as another group of biological 
researchers in France with expertise in pre-rRNA processing and how it is impaired by RP gene 
mutations.  
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Initial DBA Diagnostics 
 
Patients typically present at the clinic with the basic hallmarks of anemia including pale pallor 
and failure to thrive. After collecting the familial history of the patient, the first test is typically a 
blood smear and blood cell count. DBA may be suspected if hemoglobin (Hb) is low, with absent 
or low reticulocyte numbers and often a macrocytosis (which is age-adjusted). Fetal Hb might 
also be increased, however this is an unspecific marker that is also elevated in other bone 
marrow disease states. Most groups include a supportive eADA analysis in EDTA blood prior to 
transfusion. This DBA-specific marker is elevated in 80-90% of DBA patients. A high 
erythropoietin level may help with the diagnosis, reflecting the intrinsic defect of bone marrow in 
DBA patients. A positive family history for anemia, and/or syndromic features (present in at least 
50% of DBA patients) is also indicative of DBA. Bone marrow aspiration is performed to 
determine the content of erythroblasts, which in DBA are typically low (below 5%). In cases of 
late-onset DBA (or delayed diagnosis) e.g. in adolescents or adults, marrow might display 
hypocellularity with dysplasias and megaloblastic changes resembling low grade MDS or 5q- 
syndrome. During the initial workup, other differential diagnoses should be considered. These 
include parvovirus B19-associated pure red cell aplasia (identified by PCR analysis of bone 
marrow samples), which although rare and might present with additional pancytopenia. Other 
differential diagnosis is transient erythroblastopenia (TEC), which however usually manifests 
beyond the first year of age (and patients show normal MCV, eADA and HbF values). Unlike 
DBA, both parvovirus B19 infection and TEC are neither associated with positive family history 
nor with congenital anomalies. Sometimes, in unclear cases, clinicians might want to rule out 
other IBMFS such as Fanconi anemia or SDS. The steps that the different clinical partners of 
EuroDBA undertake in this initial non-genetic workup are shown in Table 2. 
 
 
 10 
Molecular DBA Diagnostics  
 
Because the RPS19 gene is by far the most frequently mutated gene in DBA (25% of cases), 
most screening analysis begins with targeted Sanger sequencing of RPS19 (Table 2). This 
approach uses PCR amplification and sequencing of each RP gene exon and promoter region 
by specific forward and reverse primers in both directions. The subsequent genetic diagnostics 
does not fit a “one for all” approach to identify mutations, intra-exonic, full exon or whole gene 
deletions. Based on the availability of routine and sophisticated genomic methods, different 
approaches were developed in different countries (Table 2). The first goal is to identify the most 
common genetic defects using routinely available methods such as Sanger sequencing or CGH 
array. Next generation sequencing (either targeted, or whole exome) might not yet be 
accessible to all laboratories, however recent developments in clinical diagnostics will likely lead 
to routine use of NGS instead of Sanger sequencing. Additional novel non-genetic techniques 
have been developed that reduce the time and cost of the molecular diagnosis of DBA. 
 
One newly developed method takes advantage of the fact that rRNA in cells with small RP 
mutations typically reveals an increased 28S/18S ratio, while rRNA in cells with large RP 
mutation reveals a decreased 28S/18S ratio.21 To read these ratios, a Bioanalyzer can be used 
to read rRNA levels. Ethidium bromide gels are also used to visualize if a visible 32S band 
exists, which is typically indicative of an RPL gene mutation. EBV-immortalized cells (if 
available) can be used for this technique, or T cells isolated from patient blood and 
subsequently activated with phytohemagglutinin. This method, used in Italy, can rapidly 
determine the presence of large or small ribosomal subunit defect. Such results can be helpful 
in deciding which common candidate DBA genes should then be sequenced by Sanger. 
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Since the routine use of next generation sequencing, many samples can be investigated for the 
presence of mutations in multiple RP genes at once (along with any others such as GATA1 and 
TSR2). This approach was developed within the French group of EuroDBA, and serves as a 
standard platform for other consortia members. The approach uses Roche “NimbleGen SeqCap 
EZ” library and an Illumina flowcell (Flowcell standard 2*150) with a library of 144 genes 
including 74 genes for red cell disorders. The sequences are run on a Miseq or a Nextseq, 
analyzed on a CLC Biomedical workbench (Qiagen), and the allelic variations are then verified 
by Sanger technique. Other approaches (e.g. initiated in Germany and Turkey) include 
sequencing of the few most commonly mutated RP genes using Sanger sequencing, rapidly 
followed by commercial exome sequencing in case of negative results.  
 
In case of a negative mutational result, large deletions are screened either by RP-specific MLPA 
such as in Italy or by high-resolution CGH array such as in Germany, France, and Israel. New 
bioinformatics algorithms allow for the use of whole exome data to compile copy number maps 
that can also identify microdeletions encompassing RP genes. Commercial probes and kits 
need to be verified before use since the probes might not sufficiently cover most of the RP 
genes. The percentage of DBA patients with unknown genetic cause is similar in all registries 
and can be estimated at approximately 30%. If an RP mutation or other deleterious mutation 
has not been found, exome sequencing should be performed. Ideally, this requires the 
availability of trios (both biological parents and the patient) to reduce as much as possible the 
number of variants of unknown significance that exome sequencing unfailingly reveals. 
Consanguinity is a very rare facet of DBA inheritance, and the search for novel gene mutations 
in children of consanguineous marriages usually focuses on monoallelic alterations. In index 
patients who are the only affected family members, the analysis naturally targets potentially 
pathogenic de novo variants, which however will exclude the scenario of novel mutations 
associated with silent carrier status in the parents. After exome sequencing studies, many (if not 
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the majority, according to unpublished observations from the French and German DBA 
registries) may still have unresolved genotypes. It is possible that such patients may carry 
mutations in promoter/enhancer or deep intronic regions or RP or other erythropoiesis-specific 
genes, other structural genomic anomalies might be present, or multi-genetic causes underlie 
disease manifestation. Most patients analyzed using exome sequencing will carry multiple 
potentially pathogenic variants of unknown significance, requiring lengthy molecular and cellular 
analysis to be performed before any conclusions can be drawn.  
 
DBA genotypes and phenotypes 
 
As the number of registered patients grows the more readily researchers are able to identify and 
characterize DBA clinical and cellular phenotypes in a way that would be impossible with small 
patient cohorts. Reported correlations between clinical phenotypes and mutations in specific RP 
genes include RPL5 mutations associated with physical malformations such abnormal thumbs, 
craniofacial and cardiac defects. RPL11 mutations are reported to associate with thumb 
abnormalities and mutations in RPS26 with skeletal defects.18; 42 The EuroDBA network recently 
identified a group of unrelated patients with truncating RPL15 mutations who all presented with 
very severe and early onset of anemia (hydrops fetalis in most cases). Even more remarkable 
was that within this group, the patients carrying the same point mutation in RPL15 all became 
treatment independent (in revision). Although it is widely known that between 20-25% of DBA 
become treatment-independent at some point during their lives, this is the first indication of a 
genetic association with this clinical phenomenon. The challenge of drawing meaningful 
genotype:phenotype correlations is present in any rare disease patient cohort, and is especially 
true with DBA where often there are fewer than five reported patients with a mutation in the 
same RP gene. However, with the increasing cooperation of clinics with DBA patient registries, 
such as those within the EuroDBA network, the challenge is no longer insurmountable. 
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One surprising feature of RP gene mutations is that by no means are all RPs equal, despite 
their past reputation as “housekeeping genes”. In addition to driving DBA, haploinsufficient 
mutations of RP genes are starting to be reported in non-hematopoietic congenital disorders. 
Disorders such as intellectual disability, autism, asplenia, dysmorphism, and hereditary 
nonpolyposis colorectal carcinoma are linked to inherited RP gene mutations in patients who 
have no evidence of anemia.47-51 Additionally there are a number of parents who carry the same 
RP mutation as their DBA-afflicted child yet have no clinical features at all, known as “silent 
carriers”. Although the reasons behind these differences are not well understood, there do seem 
to be some similarities in terms of the molecular consequences. For examples, in contrast with 
the asplenia-driving RP mutations, the DBA-driving RP mutations in every case studied to date 
result in ribosome biogenesis defects, including impaired pre-rRNA processing and abnormal 
ribosomal subunit formation.52; 53 52; 54  
 
The defects in ribosome biogenesis by RP gene mutations have been proposed to activate the 
TP53 tumor suppressor pathway by inducing stress in the nucleolus, the cellular organelle 
where ribosome biogenesis originates. 55 However, one of the great puzzles of DBA is why, if 
RPs are expressed in every cell in the body, are erythrocytes so specifically affected when one 
copy of an RP gene is mutated? The specificity of the defects to erythroid cells has not been 
satisfactorily explained, although theories ranging from hypersensitivity of erythroblasts to 
elevated TP53 levels, a high protein demand in rapidly dividing erythroblasts, cell-specific 
translation and splicing defects and the induction of autophagy have also been proposed as 
mechanisms that result in the reduction of erythrocyte progenitor cells.4; 55-61  
 
The collaboration between the clinical and biological researchers has allowed for advancement 
in the pathophysiology studies of DBA that would be next to impossible for any one group to 
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achieve alone. EuroDBA routinely provides examples of this level of cooperation. In one 
instance, a study published by the consortium demonstrated that DBA-linked RP gene 
mutations induce cellular autophagy. Here the German EuroDBA group generated EBV-
immortalized lymphoblast cell lines (LCLs) from patients in their registry that were then analyzed 
by the EuroDBA group of biological researchers in the Netherlands, who were performing the 
same molecular analyses on their zebrafish models of RP loss using either mutants (if available) 
or knocking down the RP of interest transiently with morpholinos. Simultaneously, the EuroDBA 
group in France performed red cell culture assays with erythroblasts infected with shRNAs to 
knock down RPS19, the resulting colonies being sent to the Netherlands for the same cellular 
analysis as was being used for the patient-derived LCLs and the zebrafish (see Figure 1).59 
 
Another example of the consortium’s capacity to cooperate on unraveling the pathophysiology 
of DBA began with the identification of a patient in the Netherlands whose exome sequence 
revealed a mutation in RPL9, a gene not previously linked to DBA. A blood sample from this 
patient was sent to the German EuroDBA partners for establishment of LCLs, a second blood 
sample was sent to the French EuroDBA partners who performed a red cell culture assay on 
isolated erythroblasts. The LCLs were subsequently sent to the biological EuroDBA partners in 
France who performed pre-rRNA analysis, and to the partners in the Netherlands who 
performed other cellular analyses including polysome profiles, TP53 analysis, proliferation and 
de novo protein synthesis measurements. The resulting colonies from the red cell culture 
assays were also analyzed for proliferation and differentiation defects as well as for TP53 
analysis. Analysis of the Netherlands group into zebrafish models of rpl9 loss confirmed the 
impairment of red cell development in mutant embryos. Taken all together, the EuroDBA 
consortium was able to determine that RPL9 is a bona fide DBA gene in a swift and systematic 
manner that would have otherwise been laborious and time-consuming (in submisison). 
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Functional validation of DBA mutations 
 
The functional validation of DBA-linked RP gene mutations may be achieved by analyzing the 
maturation of ribosomal RNA precursors by northern blot.16; 17; 20; 21; 23; 29; 52; 62; 63 Mutations in 
DBA-linked RP genes invariably lead to haploinsufficiency of the corresponding protein. Since 
most ribosomal proteins are progressively incorporated into pre-ribosomal particles 
concomitantly to pre-ribosomal RNA maturation, lack of a given RP impairs processing of pre-
ribosomal precursors (pre-rRNAs) in a specific manner.64 Modifications of the pre-rRNA pattern 
can thus be visualized by northern blot and used as a “molecular signature” for the defect of this 
RP. This characteristic pre-rRNA pattern can be determined by northern blot analysis of RNAs 
extracted from a patient's cells in order to validate the functional impact of a mutation. In case of 
a mutation in a new RP gene suspected to be pathogenic, the patient pre-rRNA profile is 
compared to that obtained after knocking down expression of the corresponding ribosomal 
protein with siRNAs in a cell line (see Figure 1A). Control samples from unrelated individuals, 
and/or unaffected parents or siblings are used for comparison. Because ribosome processing is 
affected ubiquitously in DBA patient cells, a variety of cell types can be used to prepare total 
RNAs including peripheral blood lymphocytes, LCLs, or fibroblasts. This technique is also useful 
to examine whether ribosome biogenesis is affected in patients for whom sequencing failed to 
reveal any mutation/deletion among the known DBA genes.  
 
A complementary approach consists of analyzing ribosomes from cytoplasmic fractions on 
sucrose gradients. By providing the relative abundance of small and large ribosomal subunits 
and the distribution of polysomes (translating ribosomes), this technique reveals to which extent 
a RP defect not only impairs either pathway, but also impacts translation. Figure 1 provides an 
example of coupling these techniques for a DBA patient from the EuroDBA registry, for whom 
no RP gene defect was found by sequencing. Figure 1A reveals a clear ribosome biogenesis 
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dysfunction in patient LCLs, with an accumulation of both 30S and 32S pre-rRNAs (precursors 
to rRNA constitutive of the small and the large ribosomal subunits, respectively). Quantifications 
of product to precursor ratios relative to the controls further ascertained these findings (Figure 
1A), which strongly support the diagnosis of DBA despite the lack of a candidate gene. Figure 
1B illustrates how polysome profiling revealed a substantial loss of 60S subunits in the patient 
LCLs compared to the healthy control cells, suggesting a defective RP from the large ribosomal 
subunit. Figure 1C illustrates the results of a typical o-dianisidine stain of 2-day old zebrafish 
embryos. In these experiments a mutant zebrafish line is used, if available, or morpholinos 
(MOs) that target the gene of interest are injected into the embryos at the one-cell stage. The o-
dianisidine stain at 2 days of age reveals hemoglobin-expressing red blood cells (Figure 1C, 
upper), which are clearly absent in the embryos injected with the MOs targeting an RP gene 
(Figure 1C, lower). As a final validation that patient CD34+ cells are impaired in forming 
erythrocytes, a red cell culture assay is performed (Figure 1D). Here blood is drawn from the 
patient, CD34+ cells are isolated and plated in red cell culture medium containing erythropoietin 
(EPO), stem cell factor (SCF), and interleukin-3 (IL3). After 12 days in culture the cells are 
analyzed for colony formation, cell surface determinant markers of differentiation by FACS 
analysis, protein expression by western blotting, and/or gene expression by qPCR. 
 
So far, northern blot analysis remains the method of choice to validate new DBA mutations or to 
support diagnosis of DBA. However, it is labor-intensive and not easily transposable in clinics 
due to the use of radiolabeled probes. Various commercial solutions using capillary 
electrophoresis (e.g. Agilent BioAnalyzer, Biorad Experion) exist to quantify 18S and 28S rRNAs 
that compose respectively the backbones of the small and the large ribosomal subunits. This 
straightforward technique can be used to detect biases in the 28S/18S rRNA ratio in DBA 
patient cells and determine which of the two ribosomal subunits is affected.54 This is best 
observed in RNAs extracted from peripheral blood lymphocytes (PBMCs) subjected to activation 
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by phytohemagglutinin. Although this technique is not sensitive enough to see the vast majority 
of rRNA precursors, it allows detection of an increase of 32S pre-rRNAs when the large subunit 
production is impaired. Assessment of the 18S/18S ratio is now routinely used by the Italian 
members of the consortium prior to Sanger sequencing in order to determine which of the small 
or the large subunit pathway is affected, and to prioritize the RP genes to be sequenced. In 
future years, sensitive analytical approaches adapted to pre-ribosomal precursor analyses need 
to be adapted to clinical environments, in order to routinely validate ribosome biogenesis 
defects and help diagnosis of DBA. 
 
Improving treatment and aiming for a cure 
 
The registering of DBA patients, systematic genotyping, and the continued efforts in the 
laboratory have already been invaluable for establishing important genotype:phenotype 
relationships such as those discussed above. The molecular signatures of the different RP gene 
mutations are already beginning to be used to improve diagnostics. The continuing inclusion of 
more clinical and genetic data in patient registries means at this rate it won’t be long before the 
results may be translated into meaningful patient management protocols. The hope is that in the 
future a patient’s genetic information will be able to single-handedly predict, for example, a 
successful steroid treatment, the susceptibility to iron overload upon chronic blood transfusions, 
the likelihood of undergoing treatment independence one day, or the likelihood of developing 
cancer.  
 
The other more obvious hope for the future of any rare disease is a cure. In terms of current 
treatment for DBA, steroids and blood transfusions can keep the disease at bay but these 
approaches have considerable side effects. This is especially true for chronic blood 
transfusions, which can lead to iron overload and organ failure.  The only present day cure for 
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DBA is hematopoietic stem cell transplantation (HSCT), which can be a risky procedure 
especially if a matched sibling donor is not available. To date there are no pharmaceutical 
option for DBA patients. 
 
As a monogenic blood disorder that can be cured by HSCT, one of the most exciting areas of 
future therapy for DBA is gene editing. CRISPR/Cas9 gene therapy, for example, holds great 
promise for the correction of point mutations and small indels in patient cells. For a complete 
review of how CRISPR/Cas9 functions, see reference.65 In short, this technique harnesses the 
cell’s own machinery to target specific sequences of DNA and generate small deletions which 
the cell then tries to repair. Introducing an exogenous template for this DNA repair theoretically 
allows the user to reintroduce a wild-type gene sequence at the exact position where the 
deletion was introduced, ideally at the exact site of the endogenous mutation. The beauty of this 
system is that it theoretically allows for any accessible patient cell type, such as fibroblasts, 
bladder epithelial cells, or blood-derived CD34+ cells, to be first corrected in vitro then 
dedifferentiated into HSCs that could be used for HSCT. Alternately, HSCs could first be 
generated with one of the patients’ cell types mentioned above, then the HSCs get corrected by 
CRSIPR/Cas9. The downside of this technique at the present day is that while CRISPR/Cas9 is 
indeed very efficient at generating deletions at or very near the user-specified DNA sequence, 
generating the exact desired sequence by introducing an exogenous template of wild-type DNA 
remains technically extremely challenging.  
 
Instead of correcting a mutant gene, another approach uses CRISPR/Cas9 to direct integration 
of a new wild type gene.  The “Safe Harbor” approach uses the CRISPR/Cas9 system to 
introduce an exogenous gene specifically into the AAVS1 locus on the long arm of human 
chromosome 19.66 Many reports have demonstrated high specificity of this integration site for 
the successful expression of minigenes with no adverse recombination events or fitness 
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reduction.67-69 In the context of DBA, this technique has already been used to introduce and 
drive exogenous wild type RPS19 expression in inducible pluripotent stem cells (iPSCs) derived 
from a patient carrying a truncating mutation in one allele of RPS19.70 This approach was able 
to successfully revert the ribosome biogenesis defects of the mutant cells. All this said, it should 
be kept in mind that CRSIPR/Cas9 technology is still very incipient. However when one 
considers its potential for curing monogenic inherited disorders in humans, there is no question 
that this technology will advance quickly in the near future. 
 
 
Discussion 
 
The advent of genome sequencing has resulted in significant advances in rare disease research 
this past decade. While researchers are now more likely than ever able to identify disease-
causing genes, the lack of understanding the pathphysiological mechanisms underlying these 
mutations remains a cumbersome bottleneck in terms of finding a therapeutic cure. In fact, 
according to the Kakkis EveryLife Foundation, 95% of the approximately 7,000 rare diseases 
known today do not have a single approved drug treatment.71 The funding of rare disease 
networks, such as ERARE’s EuroDBA, represents an important step forward in developing the 
foundation that will ultimately loosen this bottleneck and hasten the advance of successful 
treatment methods. 
 
DBA represents a rare disease that has amassed a worldwide network of dedicated researchers 
and patient support groups helping to fund their work. While the genetics underlying DBA are 
now very well studied, the pathophysiology still remains not well elucidated, and as such, the 
treatment options are rather outdated and limited. Some of the major questions that surround 
DBA include why is it that some patients and not others manifest physical malformations? How 
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is it that “silent carriers” have the same pathogenic RP-mutation as their affected child? And 
what are the determinants that can lead to patients undergoing treatment independence, or 
developing cancer? The establishment of cooperative global networks for DBA is a crucial step 
in being able to shed light on the drivers of this rare disease. 
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Figure Legend 
Figure 1. Functional analyses used for informal diagnostics. A) Northern blot analysis of 
LCLs from the same patient as above compared with two healthy controls lines (Ctl1 and Ctl2) 
reveals multiple pre-rRNA processing defects that are not consistent with known RPL mutations. 
Includes quantification by Ratio Analysis of Multiple Precursors (RAMP20). B) Polysomes 
profiles of healthy control LCLs (upper) show equal 40S and 60S ribosome subunit peaks while 
the profile from a patient diagnosed with DBA (lower, with no mutations in known DBA-linked 
RP genes) reveals a severe reduction of the 60S peak, consistent with an impairment of 
biogenesis of the large ribosomal subunit. C) 2-day old zebrafish embryos injected at the one-
cell stage with control MOs or MOs targetting a RP gene and then stained with o-dianisidine to 
reveal hemaglobin-expressing red blood cells (arrow). D) Red cell culture assays plate CD34+ 
cells derived from patients and helathy controls and plated in liquid culture medium (+EPO, 
SCF, IL3) for 12 days. 
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Table 1. Numbers of DBA patients reported in countries worldwide. Patient numbers were 
retrieved from recent literature, personal communications, and presentations from the 2014 
DBA Global Bridges Meeting. Population numbers were retrieved from 
http://www.worldometers.info/world-population/ on the 18th of May 2017.  = Formal registry in 
progress. DBAR = Diamond Blackfan Anemia Registry of North America. *DBAR is loosely 
affiliated with  Canada, Australia, and Mexico. 
  
Geographical Location Population (in 
millions) 
Number of 
Patients 
Formal 
Registry  
Europe, EuroDBA 
members 
   
Germany/Austria/Switzerland 80.6/8.6/8.5 330/20/30  
France 64.9 356  
Italy 59.8 239  
The Netherlands 17 44  
Israel 8.3 38  
Poland 38.6 36  
Turkey 80.4 65  
Europe, other    
Czech Republic 10.6 61  
Greece 10.9 17  
United Kingdom 65.5 104  
Lithuania 2.8 4  
Denmark 5.7 17  
Sweden 9.9 40  
Norway 5.3 22  
Finland 5.5 10  
Spain 46.1 45  
Internationally reported 
cohorts 
   
United States (DBAR) 326.2 750  
Egypt 95.2 22  
China 1400 104  
South Korea 50.7 60  
Japan 126 68  
Russia 143.4 90  
Iran 80.3 30  
Saudi Arabia 32.3 30  
 
 
 
Table 1
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Table 2. A description of the routine and molecular steps taken by different EuroDBA 
partners in the diagnosis of DBA. a tested in EDTA-blood prior initial transfusion or at least 4-
6 weeks after last transfusion. *Testing performed not routinely but rather in cases with atypical 
presentation. ‡ Genes sequenced only when following scenarios are met: GATA1, RP-genes are 
negative and the proband is male; TSR2: RP-genes are negative and the patient has typical 
facial anomalies. Abbreviations: HbF, fetal hemoglobin; eADA, erythrocyte adenosine 
deaminase; BM bone marrow; IBMFS, inherited bone marrow failure syndromes such as 
Fanconi anemia and Shwachman-Diamond syndrome; Sanger, Sanger-based sequencing; RP, 
ribosomal protein; CGH, comparative genomic hybridization; SNP, single nucleotide 
polymorphism; MLPA, multiplex ligation-dependent probe amplification. DE = Germany, FR = 
France (Paris), IL = Israel, IT = Italy, PL = Poland, TR = Turkey. 
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